Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces its membership in the Coalition for Epidemic Preparedness Innovations (CEPI) Central Lab Network (CLN). This strategic partnership represents a significant milestone in Synexa's commitment to global health security and its dedication to fostering collaboration and innovation in epidemic preparedness and response.

The CLN is the largest global group using the same methods and materials to standardise and accelerate the evaluation of vaccines against epidemic and pandemic diseases. The CLN is a key enabler of CEPI’s 100 Days Mission, which aims to reduce vaccine development timelines to just 100 days, by helping researchers and regulators to evaluate the most promising vaccine candidates quickly and accurately when faced with a future ‘Disease X’ – a newly identified pathogen with epidemic or pandemic potential.

Justin Devine, Co-Founder & Chief Innovation Officer at Synexa Life Sciences said:

"Synexa is proud to join the CLN, bolstering CEPI’s network in the Global South and aligning ourselves with the mission of epidemic preparedness and innovation. We are excited to contribute to this global effort to combat emerging infectious diseases and protect lives worldwide. Together, we can accelerate the development and equitable distribution of vaccines, ensuring that vulnerable populations have access to life-saving interventions. Joining the CLN allows us to harness the power of collaboration, innovation, standardization, and solidarity, as we work towards a healthier, safer future for all."

Emile Lens, CEO of Synexa Life Sciences commented:

"Joining CEPI symbolizes the strides Synexa has made over the last decade to become an influential, global player in the biomarker and biopharma industry. We look forward to aligning our resources and leading bioanalytical expertise with the CEPI CLN to leverage collective knowledge and aid the development and deployment of life saving vaccines all over the world".

About Synexa Life Sciences

For over two decades Synexa Life Sciences has supported biopharma clients across the globe to achieve their clinical milestones through the application of cutting-edge biomarker science. Synexa specialises in the development, validation and delivery of a wide range of complex and custom-designed assays, founded on deep expertise in immunology and the impact of the immune system on human health and candidate drug performance. Synexa is backed by Gilde Healthcare, a leading European healthcare investor.

About CEPI

CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched in 2017, to develop vaccines against future epidemics. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need.